By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to … Read more
By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 11/27/24, QuantaSing (NASDAQ:QSG) reported F1Q25 (Sep) earnings results. On a GAAP basis, QSG reported net income of $11.5 million for F1Q25, or $0.21 per ADS. That said, excluding share-based compensation expenses, adjusted EPS came in at $0.23, or below our estimate of … Read more
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) following an ‘End-of-Phase 2’ meeting on the company’s proposed plan for a Phase … Read more
People with HIV are living longer lives. That’s good news. However, it also means they’re more likely to live long enough to develop age-related diseases, such as dementia. Dementia is a loss of mental skills that affects your daily life. It can cause problems with memory, problem-solving, and learning. The risk of dementia among older … Read more
By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFU) in the second quarter … Read more